注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Intellia Therapeutics Inc是一家臨床階段的基因組編輯公司。該公司專注於使用成簇規律間隔的短回文重複序列(CRISPR)/CRISPR相關9(Cas9)技術開發治療性療法。CRISPR/Cas9是一種基因組編輯技術,即改變基因組脫氧核糖核酸(DNA)選定序列的過程。其專注於利用其模塊化平台來推進對高度未滿足需求的疾病的體內和體外治療。其主要體內候選藥物NTLA-2001用於治療轉甲狀腺素蛋白(ATTR)澱粉樣變性,以及NTLA-2002用於治療遺傳性血管性水腫(HAE)。該公司正在開發體外應用以解決免疫腫瘤學和自身免疫性疾病。其先進的體外項目包括全資持有的T細胞受體(TCR)-T細胞候選藥物NTLA-5001,用於治療急性髓性白血病(AML)和用於治療鐮狀細胞病的造血幹細胞(HSC)。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Franciscus A. G. M. Verwiel | 59 | 2017 | Independent Chairman of the Board |
John M. Leonard | 64 | 2014 | President, CEO & Director |
Andrew May | - | - | Founder and Member of Scientific Advisor Board |
Nessan Bermingham | 50 | 2014 | Founder & Member of Scientific Advisor Board |
Rodolphe Barrangou | - | - | Founder & Member of Scientific Advisor Board |
Derrick J. Rossi | - | 2015 | Founder & Member of Scientific Advisor Board |
Erik J. Sontheimer | - | - | Founder & Member of Scientific Advisor Board |
Luciano Marraffini | - | - | Founder & Member of Scientific Advisor Board |
Arthur M. Krieg | 66 | - | Member of Scientific Advisory Board |
Jesse L. Goodman | 71 | 2018 | Independent Director |
Georgia Keresty | 61 | 2021 | Independent Director |
Muna Bhanji | 60 | 2022 | Independent Director |
Beverly L. Davidson | - | 2015 | Member of Scientific Advisory Board |
Fred E. Cohen | 67 | 2019 | Independent Director |
William J. Chase | 55 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核